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ABSTRACT 26 
Ethnopharmacological relevance: Vachellia (Acacia) nilotica and other plants of this genus have 27 
been used in traditional medicine of Asian and African countries to treat many disorders, including 28 
sexually transmitted diseases, but few studies were performed to validate their anti-microbial and 29 
anti-viral activity against sexually transmitted infections. 30 
Aim of the study: The present study was undertaken to explore whether the ethnomedical use of 31 
V.nilotica to treat genital lesions is substantiated by its antiviral activity against the human 32 
immunodeficiency virus (HIV), the herpes simplex virus (HSV) and the human papillomavirus 33 
(HPV). 34 
Materials and methods: The antiviral activity of V.nilotica was tested in vitro by virus-specific 35 
inhibition assays using HSV-2 strains, sensible or resistant to acyclovir, HIV-1IIIb strain and HPV-36 
16 pseudovirion (PsV). The potential mode of action of extract against HSV-2 and HPV-16 was 37 
further investigated by virus inactivation and time-of-addition assays on cell cultures. 38 
Results: V.nilotica chloroform, methanolic and water bark extracts exerted antiviral activity against 39 
HSV-2 and HPV-16 PsV infections; among these, methanolic extract showed the best EC50s with 40 
values of 4.71 and 1.80 µg/ml against HSV-2 and HPV-16, respectively, and it was also active 41 
against an acyclovir-resistant HSV-2 strain with an EC50 of 6.71 µg/ml. By contrast, no 42 
suppression of HIV infection was observed. Investigation of the mechanism of action revealed that 43 
the methanolic extract directly inactivated the infectivity of the HPV-16 particles, whereas a partial 44 
virus inactivation and interference with virus attachment (EC50 of 2.74 µg/ml) were both found to 45 
contribute to the anti-HSV-2 activity.  46 
Conclusions: These results support the traditional use of V.nilotica applied externally for the 47 
treatment of genital lesions. Further work remains to be done in order to identify the bioactive 48 
components. 49 
 50 
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1. Introduction 51 
Vachellia nilotica, widely known by the taxonomic synonym Acacia nilotica (L.), belongs to family 52 
Fabaceae of genus Acacia containing an excess of 1350 species (Seigler et al., 2003). It is an 53 
ornamental and medicinal plant, that grows to 14-17 meters in height and 2-3 meters in diameter. It 54 
is widespread, distributed throughout tropical and sub-tropical regions of Africa, Middle East and 55 
Indian subcontinent (Bargali and Bargali, 2009; Malviya et al., 2011; Ali et al., 2012). A. nilotica is 56 
a rich source of many secondary metabolites, mainly condensed tannins, flavonoids, alkaloids. All 57 
parts of the plant (pods, bark, leaves, roots, flower, gum, branches and seeds) have been used in 58 
traditional medicine of India, Pakistan and African countries, as Kenya, Zimbabwe and Sudan, for 59 
the treatment of enteric and respiratory ailments, children’s fevers, toothache and eye complaints 60 
(Kaur et al., 2005; Ali et al., 2012; Rather et al., 2015). Interestingly, A. nilotica and other plants of 61 
Acacia genus have been used by traditional healers to treat sexually transmitted infections (STI) and 62 
HIV/AIDS-related diseases (Kambizi et al., 2001; Chinsembu et al., 2016). For instance, in 63 
Guruvedistric, Zimbawe, the A. nilotica fruits are grounded into powder and applied of penile sores 64 
a kind of lesions that can be caused either by a bacterial infection like syphilis or by a viral infection 65 
like herpes simplex virus (Kambizi et al., 2001). In Livingstone, Zambia, herbalists use A. nilotica, 66 
A.albida, A.polyacantha, A.ataxacantha and A. Schweinfurthii to treat STI like syphilis, gonorrhoea 67 
and other AIDS-related infections (Chinsembu et al., 2016). Recently, various extracts of A.nilotica 68 
have been investigated for their antibacterial (Vijayasanthiet al., 2011;Amin et al., 2013; Oladosu et 69 
al., 2013; Baiet al., 2015; Shekaret al., 2015), antiprotozoal (Jigam et al., 2010; Mann et al., 2011; 70 
Bapna et al., 2014; Alli et al., 2016), antifungal (Satish et al., 2007; Mbatchou et al., 2012; Rai et 71 
al., 2014), and antiviral activities (Hussein et al., 1999; Hussein et al., 2000; Asres et al., 2005; 72 
Rehman et al., 2011; Raheel et al., 2013; Sharma et al., 2014). The traditional use against sexually 73 
transmitted diseases and its antiviral potential prompted us to investigate on the V. nilotica antiviral 74 
activity against three sexually transmitted viruses, namely the human immunodeficiency virus 75 
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(HIV), the herpes simplex virus (HSV) and the human papillomavirus (HPV). 76 
STIs caused by bacterial and protozoan pathogens, including syphilis, gonorrhoea, Chlamydia, and 77 
trichomoniasis, are generally curable. By contrast, HIV, HSV and HPV infections are currently 78 
incurable through drug treatment (http://www.who.int/en/). 79 
According to WHO, around 36.7 million people were living with HIV at the end of 2015. The “high 80 
activity antiretroviral therapy” or HAART has transformed a terminal illness into a chronically 81 
managed disease where patients can have a near-healthy quality of life. However, to date, there is 82 
not an effective vaccine or a cure to eradicate the established infection, firstly for the high mutation 83 
rate of viral genome and its ability to escape the host immune response, secondly for the integration 84 
of provirus in cellular DNA and, thirdly for the presence of cellular and anatomical HIV reservoirs 85 
where virus maintains low level of viral replication, despite treatment (Svicher et al., 2014; Sarmati 86 
et al. 2015). Genital herpes infection, mainly caused by HSV type 2, affects more than 500 million 87 
people worldwide. These infections are mostly asymptomatic but can also cause painful blisters or 88 
ulcers in the genital or anal area (Roitzman et al., 2007). In addition, HSV-2 infection can increase 89 
the risk of HIV acquisition by approximately three-fold and genital herpes can occur in 60-90% of 90 
HIV-infected people (Freeman et al., 2006; Feng et al., 2013). HSV infections are lifelong for 91 
ability of virus to establish latency in the neurons of the sensory ganglia, therefore antiviral drugs, 92 
such as acyclovir, famciclovir, and valacyclovir, can reduce the severity and frequency of 93 
symptoms, but cannot cure the infection (Cunningham et al., 2006). Another important sexually 94 
transmitted virus is HPV, especially types 16 and 18, that cause 528000 cases of cervical cancer and 95 
266000 deaths each year. To date, no anti-HPV drugs are available to cure HPV lesions and current 96 
treatments are ablative. If for HIV and HSV-2 infections no vaccines are currently available, in 97 
recent years two safe HPV vaccines have been introduced in routine immunization programmes in 98 
65 countries (http://www.who.int/en/). Populations of developing countries with the highest rates of 99 
STIs often do not have access to adequate health services. Therefore, despite the presence of 100 
antiviral drugs for HIV and HSV-2 and HPV vaccines, their very high costs limit the administration 101 
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in people living in low-socioeconomic settings. In this contest, medicinal plants, as Vachellia 102 
nilotica, have been extensively used to treat infectious diseases in India and Africa. This study was 103 
undertaken to explore whether the ethnomedical use of V. nilotica to treat STI could be 104 
substantiated by an antiviral activity against HSV-2, HPV-16 and HIV-1. Here, we report on the 105 
cytotoxicity, the antiviral spectrum of activity of three V.nilotica bark extracts and the probable 106 
mechanisms of antiviral action of V. nilotica methanol bark extract. 107 
  108 
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2. Materials and methods 109 
2.1. Plant material 110 
The bark of Vachellianilotica L. were collected from the medicinal plant garden of Birla Institute of 111 
Technology, Mesra, Ranchi and authenticated by Botanical Survey of India, Central National 112 
Herbarium, Botanical Garden, Howrah (Letter No. CNH/Tech.II/2015/18/275 dated 23-04-2015). A 113 
specimen has been deposited at the herbarium (voucher no, SM-5). 114 
 115 
2.2. Preparation of extracts  116 
The fresh bark of Vachellia nilotica L. was completely dried at 40–45°C and pulverized in a knife 117 
grinder to fine powder (250 μm- particle diameters). The powdered bark (250 g) was then 118 
successively extracted by soxhlation using chloroform and methanol. Water extract of bark was 119 
prepared by decoction. Extracts were filtered and evaporated to dryness using a rotator evaporator 120 
under controlled temperature and reduced pressure. The obtained extracts were lyophilized and 121 
stored in desiccators (Silva et al., 2010). 122 
 123 
2.3. Phytochemical investigations of V. nilotica methanolic extract 124 
The plant extract was submitted to preliminary phytochemical screening according to the methods 125 
previously described (Manosroi et al., 2010). Briefly, Dragendorff’s reagent, Ammonia solution, 126 
Killer kiliani test, Shinoda test, Molisch test, FeCl3, Frothing test, and Salkowski test were 127 
performed to detect alkaloids, anthraquinone glycosides, cardiac glycosides, flavonoids, 128 
carbohydrate, tannins, saponins and steroids/terpenoids, respectively. 129 
 130 
2.4. Cells 131 
African green monkey kidney cells (Vero) (ATCC CCL-81) were cultured in Eagle’s minimal 132 
essential medium (MEM) (Gibco/BRL, Gaithersburg, MD) supplemented with heat inactivated 10% 133 
fetal calf serum (FCS) (Gibco/BRL). The human cervical carcinoma cell lines HeLa (ATCC CCL-134 
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2) were grown as monolayers in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco-BRL, 135 
Gaithersburg, MD) supplemented with heat-inactivated 10% FCS. The 293TT cell line, derived 136 
from human embryonic kidney cells transformed with the simian virus 40 (SV40) large T antigen, 137 
was cultured in DMEM supplemented with heat-inactivated 10% FCS and nonessential amino 138 
acids. 293TT cells allow high levels of protein to be expressed from vectors containing the SV40 139 
origin due to over-replication of the expression plasmid (Buck et al., 2005). C8166 CD4+T 140 
lymphoblastoid cell line was mantained in RPMI 1640 (GIBCO, Grand Island, NY) supplemented 141 
with 10% FCS at an optimal cell density of 0.5 to 1.5x106 cells/ml. All media were supplemented 142 
with1% antibiotic-antimycotic solution (Zell Shield, Minerva Biolabs GmbH, Berlin, Germany) and 143 
cells were grown at 37°C in an atmosphere of 5% of CO2. 144 
2.5.Viruses 145 
HSV-2 strain (ATCC VR-540) and a HSV-2 strain with phenotypic resistance to acyclovir were 146 
used. The resistant strain was generated by serial passage in the presence of increasing 147 
concentrations of acyclovir as previously described by Field et al. (1980). The resistant virus was 148 
then plaque purified, and the antiviral susceptibility was tested as described in Donalisio et al.  149 
(2016). Viral strains were propagated, collected and titrated by plaque assay on Vero cells. HIV-150 
1IIIb strain stock was prepared in C8166 cells as previously described (Bon et al., 2013). The viral 151 
stocks were titrated with an HIV-1 gag p24 antigen ELISA kit (Biomerieux, Marcy L’Etoile, 152 
France). 153 
2.6. HPV PsV production 154 
Plasmids and 293TT cells used for pseudovirus (PsV) production were kindly provided by John 155 
Schiller (National Cancer Institute, Bethesda, MD) or bought at Addgene (Cambridge, MA). 156 
Detailed protocols and plasmid maps for this study can be seen at 157 
http://home.ccr.cancer.gov/lco/pseudovirusproduction.htm.  HPV-16 PsVs were produced 158 
according to previously described methods (Buck et al., 2005). Briefly, 293TT cells were 159 
transfected with plasmids expressing the papillomavirus major and minor capsid proteins (L1 and 160 
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L2, respectively), together with a reporter plasmid expressing the green fluorescent protein (GFP), 161 
named pfwB. Capsids were allowed to mature overnight in cell lysate; the clarified supernatant was 162 
then loaded on top of a density gradient of 27 to 33 to 39% Optiprep (Sigma-Aldrich, St. Louis, 163 
MO) at room temperature for 3 h. The material was centrifuged at 28,000 rpm for 18h at room 164 
temperature in an SW41.1 rotor (Beckman Coulter, Inc., Fullerton, CA) and then collected by 165 
bottom puncture of the tubes. Fractions were inspected for purity as described in Cagno et al. (2015) 166 
and the L1 protein content of PsV stocks was determined by comparison with bovine serum 167 
albumin standards in Coomassie-stained SDS-polyacrylamide gels. 168 
2.7. HSV inhibition assay 169 
The effect of extracts on HSV-2 infections was evaluated by plaque reduction assay as described in 170 
Donalisio et al. (2014). Briefly, increasing concentrations of extracts were added to cells before, 171 
during and after infection. HSV-2 or acyclovir resistant HSV-2 were used at MOI of 0.0003 172 
pfu/cell. After 24h of incubation at 37°C, cells were fixed and stained with 0.1% crystalviolet in 173 
20% ethanol and viral plaques counted. The effective concentrations producing 50% and 90% 174 
reduction in plaque formation (EC50 and EC90) were determined using Prism software by 175 
comparing drug-treated with untreated wells. The selectivity index (SI) was calculated by dividing 176 
the CC50 by the EC50 value. As control, Vero cells were treated with Acyclovir (Sigma-Aldrich). 177 
2.8. HPV GFP-based assay 178 
HeLa cells were seeded in 96-well plates at a density of 8,000 cells/well in 100 l of DMEM 179 
supplemented with 10% FBS. The next day, serial dilutions of extracts were added to preplated 180 
cells for 2 hours at 37°C, after the incubation time the extracts were removed and mixtures of 181 
extracts and dilutions of PsV stocks at a multiplicity of infection (MOI) of 0.05 (determined by 182 
calculation of the fraction of cells positive for reporter protein expression in untreated cells) were 183 
added. The percent of infection was calculated as described elsewhere (Savoia et al., 2010). As 184 
control, cells were infected and treated with heparin (Laboratori Derivati Organici S.p.A., Milan, 185 
Italy). 186 
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2.9. HIV inhibition assay 187 
Viral stocks were assessed at concentration of 1000 ng p24/ml. HIV-1IIIb laboratory strains (5 ng/ml 188 
of HIV-1 gag p24) was pre-incubated for one hour at 37°C with increasing concentrations of 189 
extracts (0, 0.025, 0,25, 2,5, 25 g/ml) and then added to C8166 cells (0.5x106 cells/ml) for 2 hours 190 
at 37°C. After three washes in PBS, the cells were seeded at 5x105 cells/ml into fresh medium plus 191 
the drug concentration used in the pre-incubation. The HIV-1 gag p24 amount was determined 192 
seven days post-infection in the culture supernatants with the HIV-1 p24 antigen ELISA kit 193 
(Biomerieux). Mock-infected C8166 cells in medium with or without DMSO were used as the 194 
negative controls. As further control, we have treated the HIV-1IIIb-infected C8166 with serial 195 
dilutions of Tenofovir (NIBSC, London, UK). 196 
2.10. Cell viability assay 197 
HeLa and Vero cells were seeded in 96-well plates and, the next day, treated with serially diluted 198 
extracts. After 24h (Vero cells) or 72 h (HeLa cells) of incubation cell viability was determined 199 
using the Cell Titer 96 Proliferation Assay Kit (Promega, Madison, WI, USA), according to the 200 
manufacturer’s instructions. Absorbances were measured using a Microplate Reader (Model 680, 201 
BIORAD) at 490 nm. The percent of viability was calculated in comparison with the untreated 202 
control, where medium and extract solvent was added. The viability of the C8166 cells in presence 203 
of scalar concentrations of extractor Tenofovir was analysed by the Trypan Blue exclusion 204 
technique at day 7 post-infection. 205 
2.11. Mechanism of action assays against HSV-2 infection 206 
Vero cells were seeded in 96-well plates or 24-well plates in MEM supplemented with 10% FBS, 207 
for virus inactivation assay and all other assays, respectively. The following day: 208 
- In virus inactivation assay, extract (33g/ml) was added to aliquots of 105 PFU HSV-2 and 209 
incubated at 37°C for 2 h. After incubation, samples were titrated on Vero cells at high 210 
dilutions, at which the extract was not active. 211 
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- In time of addition assay, serial dilutions of extract were added on cells 2h before infection or 212 
during infection or post-infection. After the incubation time described before, viral plaques were 213 
counted. 214 
- In attachment assay serial dilutions of extract or heparin were mixed with HSV-2 and added to 215 
cooled cells and incubated for 2h at 4°C to ensure viral attachment but not entry. After two 216 
gentle washes, cells were overlaid with 1.2% methylcellulose medium, shifted to 37°C for 24h 217 
and successively plaques were counted. 218 
- In entry assay, HSV-2 at MOI of 0.01 PFU/cell was adsorbed for 2h at 4°C on pre-chilled 219 
confluent cells. Cells were then washed with cold MEM three times to remove unbound virus, 220 
treated with different concentrations of extract, and incubated for 3h at 37°C. Un-penetrated 221 
viruses were inactivated with acidic glycine for 2 min at room temperature. Cells were then 222 
washed with warm medium three times and treated. 223 
2.12. HPV inactivation assay 224 
HeLa cells were seeded in 96-well plates in 100 l of DMEM supplemented with 10% FBS. The 225 
following day a mixture of 11 μg/ml of extract and HPV-16 PsV or HPV-16 PsV (105 focus 226 
forming units) alone was incubated for 2 hours at 37°C and subsequently titrated on cells. 72 hours 227 
later the infection was measured. 228 
2.13. Data analysis 229 
All results are presented as the mean values from three independent experiments. The EC50 and 230 
EC90 values for inhibition curves were calculated by regression analysis using the software Graph- 231 
Pad Prism version 5.0 (GraphPad Software, SanDiego, California, U.S.A.) by fitting avariable 232 
slope-sigmoidal dose–response curve. For virus inactivation assays the viral infectivity in presence 233 
and absence of extract was compared using a one-way analysis of variance (ANOVA) followed by 234 
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Bonferroni test, if P values showed significant differences in virus titers. Significance was set at the 235 
95% level. 236 
  237 
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Results and discussion 238 
V.nilotica chloroform, methanol and water extracts were prepared obtaining w/w extraction yields 239 
of 6.27, 9.37 and 10.25% w/w, respectively, as previously described. In a first set of experiments, 240 
we tested the antiviral activity of three V.nilotica bark extracts against HSV-2, HPV-16 and HIV-1. 241 
Since extracts were resuspended in DMSO to a final concentration of 25 mg/ml before use, control 242 
samples with equal volumes of DMSO were included in the assay in order to rule out any cytotoxic 243 
effect ascribable to the solvent. 244 
Table 1. Antiviral activity of V.nilotica bark extracts against HSV-2, HPV-16, HIV-1and 245 
acyclovir resistant HSV-2  strain 246 
Virus Extract EC50*(µg/ml) – 
95% C.I.
 # 
EC90§(µg/ml)– 
95% C.I. 
CC50†(µg/
ml) 
SI‡ 
HSV-2 Chloroform 12.3 (7.72-19.6) 35.9 (11.4 -62.7) 189 15.4 
 Methanol 4.71 (3.11-7.12) 8.07 (2.66-24.4) 144 30.6 
 Water 10.2 (7.95-12.9) 20.1 (8.77-46.0) 190 18.6 
 Acyclovir 0.64 (0.48-0.86) 3.17 (1.69-5.95) >300 >468 
      
HPV-16 Chloroform 3.89 (1.69-8.88) 23.5 (4.15-43.4) 211 54.2 
 Methanol 1.80 (1.42-2.27) 5.48 (3.63-8.28) 58.7 32.6 
 Water 5.51 (4.58-6.63) 15.1(10.1-22.1) 115 20.9 
 
Heparin 
 
2.20 (1.83-3.01) 
 
4.3 (3.05-5.01) 
 
>300 
 
>136 
 
HIV-1IIIb Chloroform - - 74 - 
 Methanol - - 74 - 
 Water - - 74 - 
 Tenofovir 0.21 (0.12 -0.37) 1.09(0.36- 3.29) >14.3 >68.3 
      
HSV-2 ACVr¥ Methanol  6.71 (3.85-11.7)  10.5 (5.99-18.5) 144 21.5 
 
Acyclovir 
 
62.0 (57.7-65.2)  
 
> 500 
 
> 300 
 
> 5.00 
 
      
 247 
EC50* half maximal effective concentration 248 
 C.I. # confidence interval 249 
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EC90§90%effective concentration 250 
 CC50† half maximal cytotoxic concentration 251 
 SI‡ selectivity index 252 
¥ HSV-2 acyclovir resistant strain 253 
 254 
 255 
Results shown in Table 1 reveal that the three extracts were active against HSV-2 and HPV-16 PsV 256 
although at different extents. Chloroform, methanolic and water extracts inhibited HSV-2 infection 257 
with selectivity indexes of 15.4, 30.6 and 18.6, respectively, whereas they exerted anti-HPV-16 258 
activity with selectivity indexes of 54.2, 32.6 and 20.9, respectively. These data indicated that the 259 
antiviral activity was not due to cytotoxicity. Acyclovir and heparin were tested in parallel as 260 
reference inhibitors for HSV-2 and HPV-16 respectively and exerted the expected antiviral activity. 261 
By contrast, when V. nilotica bark extracts were tested on C8166 T CD4+ lymphoblastoid cells 262 
against HIV-1IIIb strain infection, no suppression of HIV infection was observed. In the same assay, 263 
the reference drug tenofovir strongly inhibited HIV-1 infection in a dose-response manner (Table 264 
1). The lack of anti-HIV-1 activity of extracts is in accord with the study by Hussein et al., that 265 
reported no HIV-1inhibitory activity of methanol and water bark extracts from Sudanese Acacia 266 
nilotica. However, it must be noted that, despite the lack of HIV-1 inhibitory activity, the extracts of 267 
the bark and the pods have been reported to exert an anti-HIV-1 protease activity (Hussein et al., 268 
1999). 269 
Although aqueous extract is mainly used in traditional medicine to treat STIs, our results 270 
demonstrated that methanolic extract is the most active one with the lowest EC50 of 4.71 and 1.80 271 
µg/ml against HSV-2 and HPV-16 infections, respectively. Therefore, the V. nilotica bark 272 
methanolic extract was chosen for further studies aimed at investigating its major mechanism(s) of 273 
action.  274 
Of note, the methanolic extract proved active also against an acyclovir-resistant HSV-2 strain 275 
(HSV-2 ACV-r) that was previously generated in our laboratory (Donalisio et al., 2016). This 276 
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finding might indicate that the active components of the extract act through a different mechanism 277 
of action to that of acyclovir, an inhibitor of viral DNA polymerase. 278 
To explore whether the extract directly inactivates HSV-2 virus particles, 105 PFU of HSV-2 and 279 
33 g/ml of extract (a dose inhibiting 90% of infectivity in previous assays, i.e. EC90) were 280 
incubated at 37°C for 2 h and, then, the samples were titrated on cells at high dilutions, at which the 281 
extract was no longer active. A 66% of inhibition of viral titers was observed indicating that the 282 
anti-HSV-2 activity of the extract depends, at least in part on the inactivation extracellular virus 283 
particles (data not shown). 284 
 285 
 286 
Fig. 1. Mode of anti-HSV-2 activity of methanol bark extract. A) Time-of-addition assays. Cells 287 
were treated with methanol bark extract for 2 h before infection (pre-treatment), for 2 h during 288 
infection or by adding the extract immediately after infection (post-infection). The number of 289 
plaques in the treated samples is expressed as a percentage of control (DMSO treated). B) HSV-2 290 
entry and attachment assays. The methanol bark extract of V. nilotica was added to the cell culture 291 
during virus-cell binding (attachment assay) or virus-cell penetration (entry assay). Heparin was 292 
used as a known inhibitor of attachment. The number of viral plaques in the treated samples is 293 
B 
A 
15 
 
expressed as a percentage of control (DMSO treated). Each point represents mean and SEM for 294 
triplicates.  295 
 296 
To investigate if bark extract is also able to target cell-surface-virus interactions or intracellular 297 
steps of the HSV-2 replicative cycle, we performed a set of time-of-addition assays in which the 298 
sample was added to the cells only before (pre-treatment), during, or after infection, and viral 299 
plaques were counted after an incubation time of 24 h. Figure 1A shows that pre-treatment with the 300 
bark extract did not affect cell susceptibility to HSV-2 infection thus excluding the possibility that 301 
components of the extract form stable interactions with one or more cellular components, 302 
preventing their interaction with viral glycoproteins. By contrast, a strong antiviral activity was 303 
observed when the extract was added during infection with EC50 values of 1.94g/ml. A modest 304 
dose-dependent effect occurred when the extract was added post-infection (EC50 of 22.5g/ml). 305 
These data bring out several considerations: 1) bark extract does not target cell-surface; 2) the 306 
extract inhibits probably also early steps of the virus replicative cycle since a significant reduction 307 
in the number of viral plaques was also observed when the extract was added to methylcellulose 308 
medium during infection. To confirm this hypothesis, an attachment and entry assays were 309 
performed (Ghosh et al., 2016). As described in Figure 1B, bark extract inhibited HSV-2 attachment 310 
to Vero cells generating a dose-response curve with EC50 of 2.74 μg/ml. A dose response curve 311 
was also obtained treating cells with heparin, a known inhibitor of attachment (EC50: 0.23 μg/ml). 312 
By contrast, performing the entry assay, a significant reduction of infectivity was only observed at 313 
highest tested concentration (66 g/ml). Then, we carried out studies to elucidate whether the 314 
mechanism of action was similar against HSV-2 and  HPV-16 PsV infections. 315 
 Interestingly, 11 μg/ml of V. nilotica extract was able to completely abrogate the infectivity of 316 
HPV-16 pseudovirions in the virus inactivation assay indicating  that bark extract exerts a virucidal 317 
activity as main mechanism of action against HPV-16 (data not shown). 318 
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Summing described results, we demonstrated the ability of V. nilotica methanol bark extract to exert 319 
a specific virucidal action against HPV-16, whereas more than one mechanism of action against  320 
HSV-2 infection, including a partial inactivation of the infectivity of virus particles and an 321 
inhibition of viral attachment to cells. These multiple antiviral actions can be attributed to several 322 
bioactive metabolites of the plant. A preliminary phytochemical screening detected saponins and 323 
flavonoids as main constituents and tannins in traces. 324 
Further work remains to be done to investigate which component is responsible for biological 325 
activity and elucidate their mechanisms of action. 326 
 327 
Overall, our findings support the traditional use of V. Nilotica extracts  for the treatment of sexually 328 
transmitted diseases due to HSV-2 and HPV-16 infections, but not due to HIV-1 infection. 329 
Interestingly, previous studies  proved an antiviral activity of extracts of Acacia nilotica also against 330 
Hepatitis C virus, that  can also be transmitted sexually, even if this mode of transmission is much 331 
less common (Hussein et al., 2000; Rehman et al., 2011; http://www.who.int/en/). Further studies 332 
are required to investigate the therapeutic potential of V. nilotica extracts for the treatment of HSV-333 
2 and HPV infections. 334 
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